Osteopore
Osteopore Ltd (ASX: OSX), a Singapore company, delivered its first custom orthopaedic device to the Hainan branch of Shanghai Ruijin Hospital on 14 July 2026, an early signal of Chinese clinical demand for bioresorbable 3D-printed bone scaffold technology entering via import rather than domestic manufacturing.
- Country
- Singapore
PCL-TCP FDM scaffold, clinical use, first China delivery Jul 2026
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| polymers-materials | ✓ | ✓ | ✓ |
Regulatorsfdareachnmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bio-printing filaments (medical) | polymers-materials | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.